Clinical Trial Update: A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive [Phase 2]

View source ↗

Summary

Phase 2 study evaluating AL-335 with odalasvir and simeprevir for chronic hepatitis C genotypes 1 or 2 in Japanese patients; completed with posted results in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• AL-335 (AL-335)
• Odalasvir (odalasvir)
• Simeprevir (simeprevir)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2019-09-11